See the DrugPatentWatch profile for Jubbonti
The cost of Jubbonti is not publicly disclosed in the provided information. Pricing for medications can vary based on factors such as insurance coverage, pharmacy, and geographical location.
How is Jubbonti administered?
Jubbonti is administered intravenously [1].
What is Jubbonti used to treat?
Jubbonti is used to treat adults with inadequately controlled type 2 diabetes mellitus [1]. It is also indicated as an adjunct to diet and exercise to improve glycemic control [1].
What are the active ingredients in Jubbonti?
Jubbonti contains the active ingredients vedolizumab and a specific dose of a proprietary formulation of a diabetes medication [1].
When was Jubbonti approved?
Jubbonti received approval in the United States on June 14, 2023 [1].
What is the drug class of Jubbonti?
Jubbonti is a combination therapy that includes vedolizumab, a selective integrin receptor antagonist, and a novel anti-diabetic agent [1]. Vedolizumab is also known as Entyvio [2].
What are the potential side effects of Jubbonti?
The provided information does not detail the specific side effects of Jubbonti. However, common side effects associated with vedolizumab, one of its components, can include upper respiratory tract infections, nasopharyngitis, and headache [2]. Patients should consult with their healthcare provider for a comprehensive list of potential side effects.
Where can I find more information about drug patents and exclusivity?
Information regarding drug patents and exclusivity can be found on DrugPatentWatch.com [3].
Sources:
1. https://www.drugpatentwatch.com/p/jubbonti-us-approval-date-and-drug-class
2. https://www.drugpatentwatch.com/p/entyvio-vedolizumab-drug-patent
3. https://www.drugpatentwatch.com/